Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Andrew John Williams has worked on the following 3 EPO patent applications which have been published in the last five years:

EP15192658

2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

IPC classification:
A61K 31/437, A61K 31/506, A61P 35/00, C07D 401/02, C07D 471/04
Applicant:
AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP15700082

PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291

IPC classification:
A61K 9/20, A61K 31/506, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca PLC
Status:
EXAMINATION REQUESTED
EP15715805

COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER

IPC classification:
A61K 31/4184, A61K 31/506, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca AB
Agent:
Andrew John Williams, AstraZeneca PLC
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature